Skip to main content

Advertisement

SpringerLink
Log in

The Hormonal Profile of Norethindrone Acetate: Rationale for Add-Back Therapy With Gonadotropin-Releasing Hormone Agonists in Women With Endometriosis

  • Review
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Gonadotropin-releasing hormone agonists (GnRHa) are an effective treatment of endometriosis-associated pelvic pain. The use of hormonal add-back therapy can alleviate the hypoestrogenic symptoms associated with GnRHa therapy, while preserving therapeutic efficacy. Norethindrone acetate (NETA) is a unique progestin that has both estrogenic and androgenic properties and is effective as an add-back regimen without estrogen supplementation. Through its estrogenic activity, NETA exerts beneficial effects on bone mineral density and vasomotor symptoms in women treated with GnRHa. In addition, NETA exhibits strong endometrial antiproliferative effects, which may result in further benefits for the endometriosis patient population. However, NETA add-back may be associated with progestogenic side effects and may lower high-density lipoprotein due to androgenic activity. These effects must be balanced with the overall benefits of NETA add-back therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. European Society of Human Reproduction and Embryology. ESHRE guideline for the diagnosis and treatment of endometriosis. 2010; http://guidelines.endometriosis.org/index.html. Accessed July 27, 2010.

  2. Gambone JC, Mittman BS, Munro MG, Scialli AR, Winkel CA. Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil Steril. 2002;78(5):961–972.

    Article  PubMed  Google Scholar 

  3. Olive DL. Gonadotropin-releasing hormone agonists for endometriosis. N Engl J Med. 2008;359(11):1136–1142.

    Article  PubMed  CAS  Google Scholar 

  4. Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? Curr Opin Obstet Gynecol. 2010;22(4):283–288.

    PubMed  Google Scholar 

  5. Agorastos T, Vaitsi V, Paschopoulos M, et al. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. Maturitas. 2004;48(2):125–132.

    Article  PubMed  CAS  Google Scholar 

  6. Olive DL. The role of add-back therapy in the United States. Drugs Today (Barc). 2005;41(suppl A):23–26.

    PubMed  Google Scholar 

  7. Surrey ES. The role of progestins in treating the pain of endometriosis. J Minim Invasive Gynecol. 2006;13(6):528–534.

    Article  PubMed  Google Scholar 

  8. Surrey ES. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group. Fertil Steril. 1999;71(3):420–424.

    Article  PubMed  CAS  Google Scholar 

  9. Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol. 1998;91(1):16–24.

    Article  PubMed  CAS  Google Scholar 

  10. Falcone T, Lebovic DI. Clinical management of endometriosis. Obstet Gynecol. 2011;118(3):691–705.

    Article  PubMed  CAS  Google Scholar 

  11. Mounsey AL, Wilgus A, Slawson DC. Diagnosis and management of endometriosis. Am Fam Physician. 2006;74(4):594–600.

    PubMed  Google Scholar 

  12. ESHRE. ESHRE guideline for the diagnosis and treatment of endometriosis 2010; http://guidelines.endometriosis.org/index.html. Accessed July 27, 2010.

  13. Fuldeore MJ, Marx SE, Chwalisz K, Smeeding JE, Brook RA. Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin. 2010; 26(3):729–736.

    Article  PubMed  CAS  Google Scholar 

  14. Stanczyk FZ. Structure–function relationships, pharmacokinetics, and potency of orally and parenterally administered progestogens intervention. In: Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 3rd ed. Burlington, MA: Academic Press; 2007:779–798.

  15. Wiegratz I, Kuhl H. Progestogen therapies: differences in clinical effects? Trends Endocrinol Metab. 2004;15(6):277–285.

    Article  PubMed  CAS  Google Scholar 

  16. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005;51(1):21–28.

    Article  PubMed  CAS  Google Scholar 

  17. Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesterone acetate. Contraception. 2006;73(6): 577–583.

    Article  PubMed  CAS  Google Scholar 

  18. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010;95(11):4909–4916.

    Article  PubMed  CAS  Google Scholar 

  19. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(suppl 1): S7-S16.

    Article  CAS  Google Scholar 

  20. Back DJ, Breckenridge AM, Crawford FE, et al. Kinetics of norethindrone in women. I. Radioimmunoassay and concentrations during multiple dosing. Clin Pharmacol Ther. 1978;24(4):439–447.

    Article  PubMed  CAS  Google Scholar 

  21. Back DJ, Breckenridge AM, Crawford FE, et al. Kinetics of norethindrone in women. II. Single-dose kinetics. Clin Pharmacol Ther. 1978;24(4):448–453.

    Article  PubMed  CAS  Google Scholar 

  22. Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 1990;42(1):67–96.

    Article  PubMed  CAS  Google Scholar 

  23. Kuhnz W, Heuner A, Humpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. Contraception. 1997;56(6): 379–385.

    Article  PubMed  CAS  Google Scholar 

  24. Chu MC, Zhang X, Gentzschein E, Stanczyk FZ, Lobo RA. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab. 2007;92(6): 2205–2207.

    Article  PubMed  CAS  Google Scholar 

  25. Burkman RT, Fisher AC, Wan GJ, Barnowski CE, LaGuardia KD. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception. 2009; 79(6):424–427.

    Article  PubMed  CAS  Google Scholar 

  26. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992;166(2): 740–745.

    Article  PubMed  CAS  Google Scholar 

  27. Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004;25(1):45–71.

    Article  PubMed  CAS  Google Scholar 

  28. Smith CL, Nawaz Z, O’Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997;11(6): 657–666.

    Article  PubMed  CAS  Google Scholar 

  29. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26(3):423–438.

    Article  PubMed  CAS  Google Scholar 

  30. Ke HZ, Chen HK, Simmons HA, et al. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone. 1997;20(1):31–39.

    Article  PubMed  CAS  Google Scholar 

  31. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol. 1999;94(3):330–336.

    PubMed  CAS  Google Scholar 

  32. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med. 1997;157(22):2609–2615.

    Article  PubMed  CAS  Google Scholar 

  33. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144(5):511–518.

    Article  PubMed  CAS  Google Scholar 

  34. Prior JC. Progesterone as a bone-trophic hormone. Endocr Rev. 1990;11(2):386–398.

    Article  PubMed  CAS  Google Scholar 

  35. Rickard DJ, Iwaniec UT, Evans G, et al. Bone growth and turnover in progesterone receptor knockout mice. Endocrinology. 2008;149(5):2383–2390.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4): 529–539.

    Article  PubMed  CAS  Google Scholar 

  37. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 1991;90(2):171–178.

    Article  PubMed  CAS  Google Scholar 

  38. Thijssen JH. Long-term effects of progestins on bone quality and fractures. Gynecol Endocrinol. 2007;23(suppl 1):45–52.

    Article  PubMed  CAS  Google Scholar 

  39. Kawano H, Sato T, Yamada T, et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A. 2003;100(16):9416–9421.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Soule SG, Conway G, Prelevic GM, Prentice M, Ginsburg J, Jacobs HS. Osteopenia as a feature of the androgen insensitivity syndrome. Clin Endocrinol (Oxf). 1995;43(6):671–675.

    Article  PubMed  CAS  Google Scholar 

  41. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331(16):1056–1061.

    Article  PubMed  CAS  Google Scholar 

  42. Abdalla HI, Hart DM, Lindsay R, Leggate I, Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol. 1985;66(6):789–792.

    PubMed  CAS  Google Scholar 

  43. Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol. 1999;106(suppl 19):1–21.

    PubMed  CAS  Google Scholar 

  44. Horowitz M, Wishart J, Need AG, Morris H, Philcox J, Nordin BE. Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density. Arch Intern Med. 1987;147(4):681–685.

    Article  PubMed  CAS  Google Scholar 

  45. Johansen JS, Jensen SB, Riis BJ, Christiansen C. Time-dependent variations in bone turnover parameters during 2 months’ cyclic treatment with different doses of combined estrogen and progestogen in postmenopausal women. Metabolism. 1990;39(11): 1122–1126.

    Article  PubMed  CAS  Google Scholar 

  46. Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years’ hormone replacement therapy on bone mineral content in postmenopausal women. Bone. 1996;19(5 suppl):191S–193S.

    Article  PubMed  CAS  Google Scholar 

  47. Pors Nielsen S, Barenholdt O, Hermansen F, Munk-Jensen N. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. Br J Obstet Gynaecol. 1994;101(4):319–324.

    Article  PubMed  CAS  Google Scholar 

  48. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update. 2006;12(2):179–189.

    Article  PubMed  CAS  Google Scholar 

  49. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21(1):248–256.

    Article  PubMed  CAS  Google Scholar 

  50. Fernandez H, Lucas C, Hedon B, Meyer JL, Mayenga JM, Roux C. One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial. Hum Reprod. 2004; 19(6):1465–1471.

    Article  PubMed  CAS  Google Scholar 

  51. Roux C, Lucas C, Briot K, Kolta S, Fechtenbaum J, Fernandez H. 3 year-follow-up of bone mineral density after a randomised trial of 12-month treatment with a GnRH agonist (leuprorelin 3.75 mg) associated with 2 options of steroidal “Add-Back” regimens in patients with endometriosis. Paper presented at: Conference title: 27th Annual Meeting of the American-Society-for-Bone-and-Mineral- Research, September 23–27, 2005, Nashville, TN, USA, Sponsor: Amer Soc Bone & Mineral Res. 2005.

  52. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75(6):1065–1079.

    Article  PubMed  CAS  Google Scholar 

  53. Goodwin JW, Green SJ, Moinpour CM, et al. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol. 2008; 26(10):1650–1656.

    Article  PubMed  CAS  Google Scholar 

  54. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331(6):347–352.

    Article  PubMed  CAS  Google Scholar 

  55. Kuhl H. Mechanisms of sex steroids. Future developments. Maturitas. 2004;47(4):285–291.

    Article  PubMed  CAS  Google Scholar 

  56. Fraser DI, Parsons A, Whitehead MI, Wordsworth J, Stuart G, Pryse-Davies J. The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study. Fertil Steril. 1990;53(3):460–468.

    Article  PubMed  CAS  Google Scholar 

  57. Activella [package insert]. Princeton, NJ: Novo Nordisk; 2006.

  58. Clarke RB. Steroid receptors and proliferation in the human breast. Steroids. 2003;68(10–13):789–794.

    Article  PubMed  CAS  Google Scholar 

  59. Soderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol. 1997;176(1 pt 1):123–128.

    Article  PubMed  CAS  Google Scholar 

  60. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol. 1999;181(2):348–352.

    Article  PubMed  CAS  Google Scholar 

  61. Conner P, Svane G, Azavedo E, et al. Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy. Fertil Steril. 2004;81(6):1617–1623.

    Article  PubMed  Google Scholar 

  62. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.

    Article  PubMed  CAS  Google Scholar 

  63. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427.

    Article  PubMed  CAS  Google Scholar 

  64. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684–1692.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Lyytinen H, Dyba T, Pukkala E, Ylikorkala O. Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland. Int J Cancer. 2010;127(1):185–189.

    Article  PubMed  CAS  Google Scholar 

  66. Stuedal A, Ma H, Bjorndal H, Ursin G. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammo-graphic density: findings from a cross-sectional study among Norwegian women. Climacteric. 2009;12(3):248–258.

    Article  PubMed  CAS  Google Scholar 

  67. SEER Cancer Statistics Review, 1975–2007. National Cancer Institute Web site. http://seer.cancer.gov/csr/1975_2007/. Accessed July 29, 2011.

  68. Speroff L, Darney PD, eds. A Clinical Guide for Contraception. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.

    Google Scholar 

  69. Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception. 1996;54(3 suppl):1S–106S.

    Google Scholar 

  70. Rosenberg L, Palmer JR, Clarke EA, Shapiro S. A case-control study of the risk of breast cancer in relation to oral contraceptive use. Am J Epidemiol. 1992;136(12):1437–1444.

    Article  PubMed  CAS  Google Scholar 

  71. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1996;347(9017):1713–1727.

    Article  Google Scholar 

  72. Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer. 1994;70(2):270–277.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477.

    Article  PubMed  CAS  Google Scholar 

  74. Bernstein P, Pohost G. Progesterone, progestins, and the heart. Rev Cardiovasc Med. 2010;11(4):228–236.

    PubMed  Google Scholar 

  75. Crews JK, Khalil RA. Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol. 1999;19(4): 1034–1040.

    Article  PubMed  CAS  Google Scholar 

  76. Earl PL, Sugiura W, Montefiori DC, et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol. 2001;75(2):645–653.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol. 1992;211(2):163–167.

    Article  PubMed  CAS  Google Scholar 

  78. Minshall RD, Pavcnik D, Browne DL, Hermsmeyer K. Nongenomic vasodilator action of progesterone on primate coronary arteries. J Appl Physiol. 2002;92(2):701–708.

    Article  PubMed  CAS  Google Scholar 

  79. Pedersen SH, Pedersen NG, Dalsgaard T, Lund CO, Nilas L, Ottesen B. Different cerebrovascular effects of medroxyprogesterone acetate and norethisterone acetate in the New Zealand White rabbit. Climacteric. 2004;7(1):12–22.

    Article  PubMed  CAS  Google Scholar 

  80. Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36(7): 2154–2159.

    Article  PubMed  CAS  Google Scholar 

  81. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril. 2001;75(5):898–915.

    Article  PubMed  CAS  Google Scholar 

  82. Kuhl H. Effects of progestogens on haemostasis. Maturitas. 1996;24(1–2):1–19.

    Article  PubMed  CAS  Google Scholar 

  83. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation. 2001;104(23): 2826–2831.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abbott Laboratories, 200 Abbott Park Dr, Abbott Park, IL, 60064, USA

    Kristof Chwalisz MD, PhD

  2. Colorado Center for Reproductive Medicine, Lone Tree, CO, USA

    Eric Surrey MD

  3. Departments of Obstetrics and Gynecology, and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Frank Z. Stanczyk PhD

Authors
  1. Kristof Chwalisz MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Surrey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Z. Stanczyk PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristof Chwalisz MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chwalisz, K., Surrey, E. & Stanczyk, F.Z. The Hormonal Profile of Norethindrone Acetate: Rationale for Add-Back Therapy With Gonadotropin-Releasing Hormone Agonists in Women With Endometriosis. Reprod. Sci. 19, 563–571 (2012). https://doi.org/10.1177/1933719112438061

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1933719112438061

Keywords

Search

Navigation